EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective

Giovanna Manzi, Roberto Badagliacca, Michele D'Alto, Stefano Ghio, Massimiliano Palazzini, Emanuele Romeo, Laura Scelsi, Edoardo Airò, Paola Argiento, Fabiana Baldi, Carolina Bauleo, Edoardo Bonsante und 31 weitere

Vascular Pharmacology · 2026

DOI: 10.1016/j.vph.2026.107590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular Pharmacology, 2026. Verfasst von Giovanna Manzi und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161…. Hauptthemen laut MEDLINE: Prostaglandins, Hypertension, Pulmonary, Antihypertensive Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer, Ministero dell’Istruzione, dell’Università e della Ricerca, MSD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The demographic shift of pulmonary arterial hypertension (PAH) patients, the expanding therapeutic armamentarium with new emerging drugs and the heterogenous experience in handling more complex therapies are making the management of PAH increasingly challenging. This project was developed to standardize PAH management across Italian centres and ensure timely access to the optimal therapeutic strategies. METHODS: A consensus document containing 10 statements, mainly focused on the use of parenteral prostanoids, was developed by eight experts in PAH during in-person and web-based meetings. Forty-six physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. RESULTS: Forty physicians participated to the survey. There was strong agreement that age and comorbidities significantly influence the choice of PAH-targeted therapies. Agreement was also reached on the use of parenteral prostanoids in the following clinical scenarios: a) treatment-naive patients at high risk; b) newly diagnosed patients classified as intermediate-risk, with severe right ventricular dysfunction assessed invasively and c) prevalent high-risk patients, as defined by the 4-strata risk score. The use of parenteral prostanoids in selected newly diagnosed intermediate-risk patients with severe right ventricular dysfunction assessed by imaging achieved a mild agreement. Three statements did not meet the predefined threshold for consensus. CONCLUSIONS: These consensus statements are intended to support physicians in starting parenteral prostanoids, minimizing delays that could negatively affect patient prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstaglandinsHypertension, PulmonaryAntihypertensive AgentsPractice Patterns, Physicians'Arterial PressureHumansItalyPrevalenceRisk FactorsTreatment OutcomeInfusions, ParenteralRisk AssessmentIncidenceClinical Decision-MakingMiddle AgedFemaleMaleAdult

Stichwörter der Autor:innen

Expert consensusItalian panelProstanoidsPulmonary arterial hypertension

Substanzen

ProstaglandinsAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
  • Pulmonary Hypertension Unit, Department of Cardiology, Monaldi Hospital, Naples, Italy.
  • Divisione di Cardiologia, Dipartimento Cardio-toraco-vascolare, Unità Scompenso Cardiaco, Trapianti e Ipertensione Polmonare, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Cardiology Unit, Cardio Thoracic and Vascular Department, S.Orsola Hospital IRCCS, Bologna University, Bologna, Italy.
  • UO Pneumologia, Fondazione Toscana G Monasterio, Pisa, Italy.
  • UOC Pneumologia, Fondazione Policlinico A. Gemelli IRCCS, Dipartimento di Neuroscienze, Organi di senso e Torace, Rome, Italy.

Förderung

  • Bayer
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • MSD
  • European Commission

Zitieren

APA

Manzi, G., Badagliacca, R., D'Alto, M., Ghio, S., Palazzini, M., Romeo, E., Scelsi, L., Airò, E., Argiento, P., Baldi, F., Bauleo, C., Bonsante, E., Carignola, R., Carmina, M. G., Cannillo, M., Casu, G., Confalonieri, M., Corda, M., Correale, M., …, & Vizza, C. D. (2026). 2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2026.107590

Vancouver

Manzi G, Badagliacca R, D'Alto M, Ghio S, Palazzini M, Romeo E, et al. 2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective. Vascular Pharmacology. 2026. doi:10.1016/j.vph.2026.107590

BibTeX
@article{Manzi2026,
  author = {Manzi, Giovanna and Badagliacca, Roberto and D'Alto, Michele and Ghio, Stefano and Palazzini, Massimiliano and Romeo, Emanuele and Scelsi, Laura and Airò, Edoardo and Argiento, Paola and Baldi, Fabiana and Bauleo, Carolina and Bonsante, Edoardo and Carignola, Renato and Carmina, Maria Gabriella and Cannillo, Margherita and Casu, Gavino and Confalonieri, Marco and Corda, Marco and Correale, Michele and D'Angelo, Luciana and De Michele, Lucrezia and Fortunato, Fabrizio and Galié, Nazzareno and Galgano, Giuseppe and Garascia, Andrea and Giuliani, Livio and Marra, Walter Grosso and Madonna, Rosalinda and Mercurio, Valentina and Monti, Simonetta and Mulé, Massimiliano and Paciocco, Giuseppe and Papa, Silvia and Pezzuto, Beatrice and Prati, Daniele and Raineri, Claudia and Romaniello, Antonella and Renon, Francesca and Stolfo, Davide and Vatrano, Marco and Vitulo, Patrizio and Manes, Alessandra and Vizza, Carmine Dario},
  title = {2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective},
  journal = {Vascular Pharmacology},
  year = {2026},
  doi = {10.1016/j.vph.2026.107590}
}
Kostenlos starten →